New drugs aiming to lower dangerous or 'bad' cholesterol in a more targeted manner could shortly be a reality, reports a new study.
Scientists from the University of Leicester and the University of California Los Angeles (UCLA) have filed two patents for developing targeted drugs that would act as a catalyst for lowering levels of low-density lipoprotein (LDL) or 'bad' cholesterol.
Cholesterol
Cholesterol is produced by the body (liver) and is essential for normal body functioning.
Advertisement
LDL is often linked to medical problems like heart disease, stroke and clogged arteries.
In the body, cells in the liver produce an LDL receptor that binds LDL and removes it from the blood, thereby lowering cholesterol levels.
The scientists have characterised an enzyme called IDOL that plays a key role in regulating the amount of LDL receptor available to bind with 'bad' cholesterol.
![Statins]( "Statins")
Statins are new wonder drugs that are proving to be efficacious, not merely in relieving symptoms but also offering several health benefits.
Therefore targeting the enzyme with drugs could increase the levels of LDL receptors present, thus lowering circulating cholesterol in humans.
"Development of a drug that interferes with IDOL's activity could help lower levels of LDL. Our research has greatly enhanced our understanding of this important process," Professor John Schwabe, Head of Biochemistry at the University of Leicester, said.
"Remarkably, IDOL only targets three proteins for degradation (all lipoprotein receptors) and this research paper greatly enhances our understanding of this specificity and identifies key residues involved in mediating this interaction."
"A potential future drug that targets IDOL could be prescribed in conjunction with statin drugs, which also cut cholesterol levels by increasing production of the LDL receptor and these two studies make considerable headway towards this," Schwabe added.
The study has been published in Genes and Development and the Proceedings of the National Academy of Science (PNAS).
Source: ANI
The scientists have characterised an enzyme called IDOL that plays a key role in regulating the amount of LDL receptor available to bind with 'bad' cholesterol.
Statins
Statins are new wonder drugs that are proving to be efficacious, not merely in relieving symptoms but also offering several health benefits.
Advertisement
Therefore targeting the enzyme with drugs could increase the levels of LDL receptors present, thus lowering circulating cholesterol in humans.
"Development of a drug that interferes with IDOL's activity could help lower levels of LDL. Our research has greatly enhanced our understanding of this important process," Professor John Schwabe, Head of Biochemistry at the University of Leicester, said.
"Remarkably, IDOL only targets three proteins for degradation (all lipoprotein receptors) and this research paper greatly enhances our understanding of this specificity and identifies key residues involved in mediating this interaction."
"A potential future drug that targets IDOL could be prescribed in conjunction with statin drugs, which also cut cholesterol levels by increasing production of the LDL receptor and these two studies make considerable headway towards this," Schwabe added.
The study has been published in Genes and Development and the Proceedings of the National Academy of Science (PNAS).
Source: ANI
Aerobic Exercise and a Diet Low in Fats Helps Keep Heart Diseases at Bay
A healthy diet combined with aerobic exercise can go a long way in preventing high cholesterol and many related heart diseases.
Advertisement
 Lipid Profile ScreeningLipid profile test/screening is done by measuring total cholesterol, HDL-cholesterol and LDL - cholesterol levels in the blood. | Advertisement
|
Advertisement
Recommended Reading
Latest Cholesterol News
New technology for identifying cholesterol levels that is cheaper, more efficient, and faster than traditional analogues developed.
New research questions the efficacy of statins prescribed to lower cholesterol levels in patients with heart disease.
Lipid profiling may provide the basis for recommending diet and lifestyle interventions before disease development of diabetes and cardiovascular disease.
Familial hypercholesterolemia is a condition in which low-density lipoprotein (LDL) levels elevate in the blood. Researchers developed a new algorithm that predicts this condition earlier in young people.
Changes in how cholesterol breaks down in the body may accelerate the progression of dementia.